CTLA4 and neoplasm: In the tumor microenvironment, ICBs block the co-inhibitory receptors of T cells, such as PD-1 and CTLA-4, and inhibit the inhibitory signals of antigen-specific T cells, enabling them to attack tumor cells more effectively.